Grace Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed Jun 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Jun 18, 2026

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

Balance Sheets

	March 31, 2026	March 31, 2025
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	16,977	22,133
Receivables	20	126
Prepaid expenses	383	453
Total current assets	17,380	22,712
Equipment, net	8	15
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	66,654	71,993
Liabilities and stockholders’ equity
Current liabilities:
Trade and other payables	2,146	1,930
Total current liabilities	2,146	1,930
Derivative warrant liabilities	—	1,141
Deferred tax liability	612	2,312
Total liabilities	2,758	5,383
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025	—	—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively	1	1
Additional paid-in capital	298,413	293,334
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(228,480)	(220,687)
Total stockholders' equity	63,896	66,610
Total liabilities and stockholders’ equity	66,654	71,993

Consolidated Statements of Loss and

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.